Eccentric Cycling Exercise During Pulmonary Rehabilitation in Patients With Cardiopulmonary Diseases
1 other identifier
interventional
24
1 country
2
Brief Summary
Eccentric cycling exercise (ECC) allows training at low metabolic costs and may therefore be valuable for patients with pulmonary vascular disease (PVD). For these patients, regular exercise training has an evidence level 1A recommendation in the current guidelines. Exercise training during longer and regular periods provides chronic adaptation, for which ECC was recently found to have a greater effectiveness than CON by increasing muscle strength, hypertrophy, six-minute walking distance and furthermore, by increasing maximum oxygen uptake (V'O2max) especially in patients with chronic obstructive pulmonary disease (COPD), chronic left heart failure or coronary heart disease. Furthermore, we conducted an RCT in which we exposed patients with PVD to ECC and concluded that ECC is a feasible and well-tolerated exercise modality for PVD patients with severely lower O2 demand and load to the right ventricle. The study in patients with PVD was started (EccRehab), and the great potential was recognized. Therefore there was an indication to open the inclusion criteria to all cardiopulmonary patients with indication for pulmonary rehabilitation (EccRehab2). For this purpose, the aim of this project is to investigate whether ECC improves exercise capacity and possibly hemodynamics during prolonged rehabilitation programs in patients with cardiopulmonary diseases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2025
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 2, 2025
CompletedFirst Submitted
Initial submission to the registry
June 10, 2025
CompletedFirst Posted
Study publicly available on registry
June 29, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 30, 2026
June 29, 2025
June 1, 2025
1.1 years
June 10, 2025
June 19, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Peak exercise performance [Watts]
Peak exercise performance is measured during cardiopulmonary exercise tests on a cycle ergometer. The Unit of the measurement is watts.
At baseline pre-intervention and immediately after three weeks of rehabilitation
Secondary Outcomes (14)
Peak oxygen uptake [L/min]
At baseline pre-intervention and immediately after three weeks of rehabilitation
Ventilatory equivalents for carbon dioxide (Minute ventilation / carbon dioxide output)
At baseline pre-intervention and immediately after three weeks of rehabilitation
Six minute walk distance [meters]
At baseline pre-intervention and immediately after three weeks of rehabilitation
Knee extension test [repetitions]
At baseline pre-intervention and immediately after three weeks of rehabilitation
Systolic pulmonary arterial pressure [mmHg]
At baseline pre-intervention and immediately after three weeks of rehabilitation
- +9 more secondary outcomes
Study Arms (2)
Eccentric cycling
EXPERIMENTALPatients perform eccentric cycling exercise instead of normal cycling exercise in addition to standard car during a cardiopulmonary rehabilitation
Standard care
ACTIVE COMPARATORPatients perform cardiopulmonary rehabilitation according to standard care
Interventions
Patients perform eccentric cycling exercise instead of normal cycling exercise in addition to standard car during a cardiopulmonary rehabilitation
Patients perform cardiopulmonary rehabilitation according to standard care
Eligibility Criteria
You may qualify if:
- Diagnosed with PVD, either PAH or CTEPH via right heart catheterization, according to recent guidelines \[9\]
- Diagnosed with a cardiopulmonary disease as indication for a pulmonary rehabilitation
- Stable medication for at least 1 month
- Age 18years to 85 years
- No resting hypoxemia (PaO2 \>7.3 kPa)
- Medical indication to prescibe a pulmonary rehabilitation
You may not qualify if:
- Any co-morbidity that limits the patient to participate the full rehabilitation
- Enrollments in other trials with active treatments
- Language barriers that limits the patient to participate in the rehabilitation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Silvia Ulrich Somainilead
- Klinik Barmelweidcollaborator
Study Sites (2)
Klinik Barmelweid
Barmelweid, 5017, Switzerland
Universitätsspital Zürich
Zurich, 8092, Switzerland
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Prof. Silvia Ulrich
Study Record Dates
First Submitted
June 10, 2025
First Posted
June 29, 2025
Study Start
May 2, 2025
Primary Completion (Estimated)
May 30, 2026
Study Completion (Estimated)
May 30, 2026
Last Updated
June 29, 2025
Record last verified: 2025-06